RxDoctor Payments Data

Dillon Sedaghatpour, MD

Orthopaedic Surgery · Carle Place, NYNPI 1669962924

Payments from drug & device makers

$5,782in general payments, 2019–2025

Across 55 payments — averaging $105.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Arthrex$2K
  • Suvon Surgical LLC$609
  • Zimmer Biomet$574
  • Skeletal Dynamics Inc$298
  • Polynovo North America LLC$214
  • plus $342 from 5 others

What the payments were for

  • Travel & lodging$2,43042%
  • Food & beverage$3,35258%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker15$2,171
Arthrex19$1,574
Suvon Surgical LLC7$609
Zimmer Biomet4$574
Skeletal Dynamics Inc2$298
Polynovo North America LLC1$214
Globus Medical1$146
Johnson & Johnson1$91
Polaris Technology Solutions LLC2$42
Medical Device Business Services, Inc.2$40
Inspire Medical Systems, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,782 in reported general payments places this provider in the 55th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$11,026
Medicare patients
34
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam22$35

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Carle Place

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →